Gastrointestinal disorders include both functional and motility disorders affecting the gastrointestinal tract. Functional disorders involve an abnormality in the working of the gastrointestinal tract. They are the most common type of disorders and present with disturbances in motility, visceral hypersensitivity, changes in the mucosal and immune function, variations in central nervous system processing, and altered gut microbiota. Motility disorders are characterized by changes in the movement of the gastrointestinal tract and the transfer of its contents. Some of the most common gastrointestinal functional and motility disorders include IBS, GERD, Crohn’s disease, ulcerative colitis, and peptic ulcers.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Pipeline portfolio

Ulcerative colitis

Crohn's disease

IBS

PART 06: Market landscape

Global gastrointestinal therapeutics market

PART 07: Market segmentation by disease type

Overview

PART 08: Global IBD therapeutics market

Global ulcerative colitis drugs market

Global Crohn's disease drugs market

Market segmentation by molecule type

PART 09: Global IBS therapeutics market

PART 10: Global gastrointestinal OTC drugs market

PART 11: Geographical segmentation

Global gastrointestinal therapeutics market by geography

2015-2020

Gastrointestinal therapeutics market in Americas

Gastrointestinal therapeutics market in EMEA

Gastrointestinal therapeutics market in APAC

PART 12: Market drivers

Increasing consumption of biologics

Tentative approval of late stage molecules

Development of novel therapies using innovative

technologies

Improved diagnostic tools increasing the treatmentseeking

population

PART 13: Impact of drivers

PART 14: Market challenges

Increased consumption of OTC medications

Unknown etiology of IBD and IBS

Discontinuation of drugs under development and from

the market

PART 15: Impact of drivers and challenges

PART 16: Market trends

Patient assistance programs

Emergence of biosimilars

Rise in self-medication

Focus on regenerative medicines

Strategic alliances and M&A

PART 17: Vendor landscape

Competitive scenario

Other prominent vendors

PART 18: Key vendor analysis

AbbVie

Johnson & Johnson

Takeda

Allergan

UCB

PART 19: Appendix

List of abbreviations

PART 20: Explore Technavio